| Name | Mirtazapine |
| Description | Mirtazapine (6-Azamianserin) is a tetracyclic antidepressant with a somewhat unique mechanism of action. Mirtazapine therapy can be associated with transient asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent acute liver injury. |
| In vitro | Mirtazapine displays marked affinity for cloned, human alpha2A-adrenergic (AR) receptors at which it blocks noradrenaline (NA)-induced stimulation of guanosine-5'-O-(3-[35S]thio)-triphosphate ([35S]-GTPgammaS) binding. Mirtazapine shows high affinity for cloned, human serotonin (5-HT)2C receptors at which it abolishes 5-HT-induced phosphoinositide generation. Mirtazapine markedly elevates dialysate levels of NA and, in FCX, DA, whereas 5-HT is not affected.[1] Mirtazapine enhances the effectiveness of the electrical stimulation of the ascending 5-HT pathway by blocking both alpha-2 adrenergic auto- and heteroreceptors. Mirtazapine blocks the suppressant effect of microiontophoretically applied norepinephrine (NE) on the firing activity of CA3 dorsal hippocampus pyramidal neurons, indicating their antagonistic effects on postsynaptic alpha-2 adrenoceptors. [2] |
| In vivo | Mirtazapine (10-250 mg/kg i.v.) enhances dose-dependently the firing activity of the 5-HT neurons in naive rats, but not in 6-hydroxydopamine-pretreated rats. [2] Mirtazapine (5 mg/kg/day, s.c., using osmotic minipumps) increases the spontaneous firing activity of locus coeruleus noradrenaline (NA) neurons in male Sprague-Dawley rats. Mirtazapine antagonizes both the enhancing effect of a low dose (10 mg/kg, i.v.) and the reducing effect of a high dose (100 mg/kg, i.v.) of the alpha 2-adrenoceptor agonist clonidine on the effectiveness of the electrical stimulation of the ascending 5-HT pathway in suppressing the firing activity of dorsal hippocampus CA3 pyramidal neurons. [3] Mirtazapine (5 mg/kg s.c.) only slightly affects DOPAC and homovanillic acid levels in the striatum, hardly affects 5-HT release in freely moving rats, but clearly increased 5-hydroxyindole acetic acid. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 53 mg/mL (199.74 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 55 mg/mL (207.27 mM), Sonication is recommended.
|
| Keywords | κ-opioid receptor | α2-adrenoceptor | TNFα | Sert (Sodium-dependent) | Serotonin Receptor | serotonergic | Org-3770 | Org 3770 | oral | OpioidReceptor | Opioid Receptor | noradrenergic | Mirtazapine | Inhibitor | inhibit | HT | HistamineReceptor | Histamine Receptor | DopamineReceptor | Dopamine Receptor | Dopamine | DA transporter | Beta Receptor | autoimmune | Antidepressant | AdrenergicReceptor | Adrenergic Receptor | 61337-67-5 | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT3 | 5-HT2 | 5-HT Receptor | 5HT Receptor | 5-HT |
| Inhibitors Related | Alverine citrate | Meclizine dihydrochloride | Dapoxetine hydrochloride | Clozapine N-Oxide | Lidocaine | Famotidine | Octopamine hydrochloride | Sodium butanoate | D-Menthol | Oxolinic acid | Alginic acid | Trazodone hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
